Gilead Sciences Announces Third Quarter 2023 Financial Results

07.11.2023 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023. “Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by ...

Related Keywords

United States ,Foster City ,California ,Ireland ,American ,Ledipasvir Sofosbuvir ,Sofosbuvir Velpatasvir ,Complera Eviplera ,Drug Administration ,Gilead Foundation ,Gilead Sciences Inc ,Merck Sharp Dohme ,Gilead Public Affairs Department ,Asegua Therapeutics ,Gilead Sciences Stock ,Merck Co Inc ,Janssen Sciences Ireland Unlimited Company ,Mirobio Ltd ,Assembly Biosciences Inc ,Tmunity Therapeutics Inc ,European Commission ,Tentarix Biotherapeutics Inc ,Nasdaq ,Other International ,Gilead Sciences ,Xinthera Inc ,Earnings Per Share ,Liver Disease ,Gross Margin ,Operating Expenses ,Effective Tax ,Forward Looking Statements ,Infectious Disease Week ,American Association ,Liver Diseases ,Assembly Biosciences ,Lung Cancer ,Private Securities Litigation Reform Act ,Epic Bio ,Safe Harbor ,Private Securities ,Litigation Reform Act ,Merck Sharp ,Cell Therapy ,Janssen Sciences Ireland Unlimited ,Gilead Sciences Chart ,Ilead Sciences Kurs ,Ilead Sciences Aktie ,